Enanta Pharmaceuticals Inc. | Ownership
Companies that own Enanta Pharmaceuticals Inc.
BlackRock Fund Advisors
2,245,146
11.59%
84,222
0.01%
06/30/2018
Farallon Capital Management LLC
1,075,000
5.55%
160,000
0.64%
06/30/2018
The Vanguard Group, Inc.
1,062,754
5.48%
211,831
0%
06/30/2018
Renaissance Technologies LLC
878,500
4.53%
33,600
0.08%
06/30/2018
T. Rowe Price Associates, Inc.
855,491
4.42%
537,087
0.01%
06/30/2018
SSgA Funds Management, Inc.
770,299
3.98%
12,500
0.01%
06/30/2018
Dimensional Fund Advisors LP
593,847
3.07%
537
0.01%
06/30/2018
First Manhattan Co.
569,408
2.94%
-302,367
0.28%
06/30/2018
Krensavage Asset Management LLC
519,035
2.68%
-220,703
12.09%
06/30/2018
Invesco Capital Management LLC
445,594
2.29%
41,459
0.03%
06/30/2018
| Address |
500 Arsenal Street
Watertown Massachusetts 02472
United States
|
|
Employees
|
- |
| Website |
http://www.enanta.com |
| Updated |
07/08/2019 |
| Enanta Pharmaceuticals, Inc. engages in the research and development of small molecule drugs for the treatment of viral infections and liver diseases. It offers the two protease inhibitors Maviret and the Viekira Pak for the treatment of chronic hepatitis C virus. The company was founded by Peter O. |
